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Abstract
Background: Uncomplicated urinary tract infections (UTI) are usually treated with antibiotics as recommended by
primary care guidelines. Antibiotic treatment supports clinical cure in individual patients but also leads to emerging
resistance rates in the population. We designed a comparative effectiveness study to investigate whether the use of
antibiotics for uncomplicated UTI could be reduced by initial treatment with ibuprofen, reserving antibiotic
treatment to patients who return due to ongoing or recurrent symptoms.
Methods/design: This is a randomized-controlled, double-blind, double dummy multicentre trial assessing the
comparative effectiveness of immediate vs. conditional antibiotic therapy in uncomplicated UTI. Women> 18
and< 65 years, presenting at general practices with at least one of the typical symptoms dysuria or frequency/
urgency of micturition, will be screened and enrolled into the trial. During an 18- months recruitment period, a
total of 494 patients will have to be recruited in 45 general practices in Lower Saxony. Participating patients receive
either immediate antibiotic therapy with fosfomycin-trometamol 1x3g or initial symptomatic treatment with
ibuprofen 3x400mg for 3 days. The ibuprofen group will be provided with antibiotic therapy only if needed, i.e. for
persistent or worsening symptoms. For a combined primary endpoint, we choose the number of all antibiotic
prescriptions regardless of the medical indication day 0–28 and the “disease burden”, defined as a weighted sum of
the daily total symptom scores from day 0 to day 7. The study is considered positive if superiority of conditional
antibiotic treatment with respect to the first primary endpoint and non-inferiority of conditional antibiotic
treatment with respect to the second primary endpoint is proven.
Discussion: This study aims at investigating whether the use of antibiotics for uncomplicated UTI could be reduced
by initial treatment with ibuprofen. The comparative effectiveness design was chosen to prove the effectiveness of
two therapeutic strategies instead of the pure drug efficacy.
Trial registration: Clinicaltrials.Gov: NCT01488955
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Background
Uncomplicated urinary tract infections (UTI) are a com-
mon condition in general practice. To date, they are
usually treated with antibiotics, as recommended by pri-
mary care guidelines [1-3] - resulting in effective and
fast symptom resolution. However, this approach
accounts for a substantial number of antibiotic prescrip-
tions in primary care with inherent disadvantages [4].
The increasing use of antibiotics is the main reason
for emerging resistance rates [5,6]. More than 20% of E.
coli, the most common uropathogens, are resistant to
trimethoprim-sulfomethoxazole and to cephalosporins
[7]; for fluoroquinolons the same trend can be observed.
Since less antibiotic prescribing is associated with lower
levels of antibiotic resistance [8,9], efforts should be
made to reduce unnecessary prescriptions [10,11]. Up to
now, only few randomized-controlled trials compared
antibiotic treatment with placebo or different thera-
peutic strategies, i.e. empirical, targeted or delayed anti-
biotic treatment in uncomplicated UTI [12-14]. These
trials suggested that in many cases uncomplicated UTI
are a self limiting condition. Results showed delayed
symptomatic and bacteriological cure in the placebo and
in the delayed prescription group, but no serious com-
plications [4,7,12,14]. The failure rate in the placebo
group due to symptom persistence/worsening was con-
sidered a strong argument in favour of antimicrobial
treatment [10]. In 2007/2008, the authors carried out a
randomized controlled pilot trial comparing ibuprofen
and ciprofloxacin in uncomplicated UTI with regard to
symptom course Non-inferiority of ibuprofen could be
demonstrated based on a sample size of 79 patients.
Symptomatic treatment was sufficient for 66% (24/36)
patients in the ibuprofen-group, with secondary anti-
biotic treatment rates of 33% (12/36) versus 18% (6/33)
in the ibuprofen and ciprofloxacin groups respectively
[15]. In view of the symptomatic treatment as alternative
treatment option for uncomplicated UTI, we designed a
comparative effectiveness study with the aim to investi-
gate whether the use of antibiotics for uncomplicated
UTI could be reduced by initial treatment with ibupro-
fen, reserving antibiotic treatment to patients who re-
turn due to ongoing or recurrent symptoms.
Our main research questions are: 1) Does conditional
antibiotic use in patients with uncomplicated UTI re-
duce the number of antibiotic prescriptions without sig-
nificant increase in symptoms or recurrent episodes/
complications? 2) Is the proposed strategy safe in terms
of complications and recurrences?
Methods
Design
This is a randomized-controlled, double-blind, double
dummy multicentre trial assessing the comparative
effectiveness of immediate vs. conditional antibiotic
therapy in uncomplicated UTI.
Patients
Inclusion criteria
Women> 18 and< 65 years with suspected UTI, present-
ing at general practices with at least one of the typical
symptoms dysuria or frequency/urgency of micturition.
Written informed consent is required.
Key exclusion criteria are any signs of complicated in-
fection (temperature> 38 °C, pain on renal bed percus-
sion; any conditions that may lead to complicated
infections (i.e. pregnancy, renal diseases, immunosup-
pressive therapy); current antibiotic therapy, current in-
take of NSAIDs, current intake of drugs interacting with
the trial drugs (anticoagulants, corticosteroids) contrain-
dications or allergies for trial drugs; renal diseases (renal
failure; urinary tract abnormalities or past urinary surgery,
urinary catheterization); history of gastrointestinal ulcers;
serious neurological diseases (epilepsy, multiple sclerosis,
paraplegia); disability to understand trial information.
Setting and recruitment
The trial will be carried out in general practices in
northern Germany. A total of 494 patients will have to
be recruited in 45 investigator sites (general practices)
during an 18- months recruitment period. Women pre-
senting with UTI symptoms will be screened and en-
rolled by their GP.
To achieve the recruitment goal as soon as possible,
high emphasis will be put on structured practice support
to optimize patient recruitment (i.e. newsletters, tele-
phone calls, incentives).
Intervention/trial drug
Participating patients receive either immediate antibiotic
therapy with fosfomycin-trometamol 1x3g or initial
symptomatic treatment with ibuprofen 3x400mg for
3 days. Antibiotic therapy will be only provided if
needed, i.e. for persistent or worsening symptoms.
Fosfomycin for oral treatment is only available as gran-
ules. Thus, a double-dummy-design is required with the
intervention group taking placebo granule sachets 1x1
additional to 3x400 mg ibuprofen tablets and the control
group taking placebo tablets 3x1/3 days additional to
fosfomycin-trometamol.
During the entire trial, long term medication or co-
medication should be prescribed and taken as usual.
Patients will be told to avoid taking spasmolytic drugs. Any
further medication will be documented in Case Report
Form (CRF). If secondary antibiotic treatment is required
due to ongoing/worsening symptoms, antibiotics should be
chosen in line with the results of the urine culture at day 0.
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In order to guarantee concealment a central randomization
on patient level will be performed. Code numbers will be
assigned from the random list to the drug units in blocks of
six and distributed to the participating practices. At inclu-
sion, the code number will be assigned and the drug pack-
age will be transferred to the patient by the GP.
Procedures
Day 0/inclusion
Patients complete a symptom questionnaire and provide
a urine specimen for culture, dipstick and pregnancy
test. Temperature will be taken oral or auricular. The
GP hands over the blinded trial drug and instructs the
patient to reconsult in case of persistent or worsening
symptoms, or in case of fever. In uncomplicated cases
the number of mandatory study visits will be restricted
to day 0. If the patient returns within three days with
persistent or worsening symptoms of UTI, the study
drug will be discontinued and replaced by an antibiotic
at the discretion of the GP, chosen in line with urine cul-
ture results if available. Recurrent UTI after the end of
the study treatment will be treated with antibiotics at
the discretion of the GP. All urine cultures will be per-
formed in one central laboratory. Native urine will be
transported within 24 h to the laboratory; in the mean-
time it will be stored in the refrigerator.
Data collection and management
Inclusion
Patients complete a piloted symptom questionnaire
to score severity of each symptom (dysuria, fre-
quency and low abdominal pain). Symptoms will be
scored from 0 (not at all) to 4 (very strong), and
symptom scores will be added to a maximal sum
score of 12 points. The symptom questionnaire has
already been piloted in the study “HWI-01” in 79
patients. Additionally, patients will record the UTI-
related impairment in daily live-activities by the
Activity Impairment Assessment (AIA) [16].
Demographic and clinical data and laboratory
results will be documented by the practice staff in
an internet-based database (eCRF).
Follow up
Further symptom assessment will be conducted via
telephone interviews by the study nurses of the Uni-
versity Departments' research teams. Symptom
related data and impairment in daily live-activities
(AIA) will be scored according to the symptom
questionnaire at inclusion. Additionally, cause, dur-
ation and dosage of any antibiotic prescriptions will
be recorded, as well as adverse events. Telephone
interviews will be conducted on day 1, 3, 5 and 7, or
until resolution of symptoms. During this time,
patients will complete a symptom diary daily to col-
lect continuous data by telephone interviews.) The
last telephone interview will take place on day 28.
To complete follow-up data in terms of recurrences
and safety information, further interviews will be
conducted after 6 and 12 months (Figure 1).
Outcomes
Primary endpoints
Two co-primary endpoints measuring number of anti-
biotic prescriptions and disease burden are considered.
First co-primary endpoint Number of all antibiotic pre-
scriptions regardless of the medical indication day 0–28.
Second co-primary endpoint The “disease burden“will
be calculated as weighted sum of the daily total
symptom scores from day 0 to day 7. The weights
are chosen in a way that the measure represents the
area under curve (AUC) below the total symptom
score as a function of time.
Key secondary endpoints
Sum of daily defined doses (DDD) per patient; pro-
portion of patients with/number of recurrent UTI
episodes within 28 days/6/12 months, defined by the
re-occurrence of UTI symptoms after symptom reso-
lution; proportion of symptom-free patients at day 4
and 7; total disease burden (AUC) until day 4; disease
burden related to each of the three symptoms until
day 7; activity impairment assessment (AIA) day 1 to
day 7; number of complications (febrile UTI, pyelo-
nephritis/septic syndrome) and the number of adverse
events.
The defined daily doses (DDD) are based on the official
ATC-Index for Germany 2010 [17], which is derived from
the WHO-index 2010 [18].
“Symptom-free” is defined as a total symptom score of 0.
Statistical analysis and reporting
The primary analysis will be based on the results of two
statistical tests. The first test (superiority) will be on the
following two hypotheses with respect to the first co-
primary endpoint:
H0: The number of antibiotic prescriptions within the
interval 0–28 days in the conditional use group is
greater than or equal to the corresponding number in
the immediate use group.
vs.
H1: The number of antibiotic prescriptions within
the interval 0–28 days in the conditional use group
is lower than the corresponding number in the
immediate use group.
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The second test (non-inferiority) will be on the follow-
ing two hypotheses with respect to the second co-
primary endpoint:
H0: The disease burden within the interval 0–7 days in
the conditional use group is greater than or equal to
125% of the corresponding disease burden in the
immediate use group.
vs.
H1: The disease burden within the interval 0–7 days in
the conditional use group is less than 125% of the
corresponding disease burden in the immediate use
group.
Since both criteria have to be fulfilled for the study
being positive, the intersection hypothesis has to be
proven. This can effectively be achieved by a closed test-
ing procedure where both hypotheses are tested hier-
archically at a level of 2.5% one-sided, i.e. the second
hypothesis will only be tested if the first test was
significant.
Formally, hypothesis (i) will be tested non-parametrically
using an exact Mann–Whitney rank sum test since the
distribution of antibiotic prescriptions will be discrete and
is not expected to follow a known standard distribution.
The test will be performed in the intention-to-treat (ITT)
population consisting of all patients randomized with at
least one report on antibiotic use. For hypothesis (ii) to be
tested, a covariance analysis of the log disease burden will
be performed with the random group as factor and the
day-0 (inclusion) log sum of symptom scores as covariate.
Logarithms were chosen since the pilot study suggested
that the distribution of disease burden was approximately
normal after this transformation was applied. From this
model, a two-sided 95% confidence interval for the ratio of
the expected total disease burdens of conditional use vs.
immediate use will be calculated by back-transformation
(exponentiation) of the corresponding interval in log-units
to the original scale. If this interval will lie entirely below
1.25, non-inferiority of conditional use therapy as compared
to immediate use therapy can be stated. We pre-defined
the margins of equivalence to be 80% to 125% as these mar-
gins are understood as minimum clinically relevant devia-
tions. The analysis will be performed in the per protocol
(PP) population consisting of all patients randomized with
complete symptom score over 7 days and therapy in line
study completion
female patients with UTI symptoms 
fulfilling inclusion criteria
informed consent
randomization to trial treatment, baseline data
1x1 placebo granule sachet 
3x400 mg ibuprofen tablets (3 
days)
1x1 fosfomycin-trometarol granule 
sachet












telephone-interview: evaluation of symptoms, activity impairment-
assessment, antibiotic intake,  AE, SAEda
y 
28













Figure 1 Study plan. Abbreviations: UTI= Urinary Tract Infection, AE= Adverse Event, SAE= Serious Adverse Event, AIA= Activity Impairment
Assessment.
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with the study protocol. The analysis will be repeated in the
ITT population to judge the validity of the per-protocol
result.
Missing values will pose a serious challenge to the val-
idity of the analysis since up to 15% premature study ter-
minations due to non-compliance or withdrawal of
consent are to be expected. For the ITT analyses, some
kind of imputation of missing values in the co-primary
endpoints is required. We thus decided to perform two
ITT analyses for each endpoint. The primary analysis
uses multiple imputations of missing values based on
the available information. Last observation carried for-
ward analysis will also be performed as an additional
conservative sensitivity analysis. The technical details
will be defined in a statistical analysis plan after a blind
review of the data, before code break.
Secondary endpoints will be analyzed by Mann–
Whitney-U Tests tests (numbers) or analogous to the
second co-primary endpoints, i.e. calculation of between-
group differences or ratios with 95%-confidence limits, tak-
ing the different scale types into account. To characterise
patients who will need antibiotic treatment in the condi-
tional use group, an exploratory logistic regression analysis
will be performed.
Sample size
The sample sizes required for the superiority and the
non-inferiority part of the trial were based on the results
of the pilot study, but were chosen rather conservative.
For the superiority part, antibiotic prescription rates of
50% and 90% were assumed for conditional and immedi-
ate use, resulting in a sample size of 2x29 = 58 patients
to yield a power of 90%. For the non-inferiority part, a
coefficient of variation of 80% was assumed for disease
burden, resulting in a sample size of 2x210 = 420
patients to reach a power of 90% for the case of zero
group difference. Thus, the second hypothesis drives the
sample size. With an assumed drop-out rate of 15% for
the PP population, 494 patients have to be randomized.
Calculations were done using PASS 2008.
Safety
At inclusion, patients will be instructed to reconsult at
any time in case of ongoing/worsening symptoms. For
this case, an immediate specific antibiotic therapy can be
provided based on the urine culture at inclusion.
Adverse events (AE) leading to practice consultation
will be documented by the GP; minor AEs will be ac-
tively asked for during telephone interviews. Serious AE
and patients reconsulting with fever will have to be
reported immediately. An independent Data and Safety
Monitoring Board is established to examine safety risks
based on the safety related data regularly.
Adverse events rates in both groups serve as safety out-
comes and will be compared in data analysis. Late follow
ups after 6 and 12 months serve to collect observational
data of recurrences and other renal complications.
Ethical considerations
Ethical approval has been obtained by the Independent
Ethics Committees of the Hannover Medical School
(No. 5986 M). The study will be conducted according to
the principles of Good Clinical Practice.
Informed consent is taken by the GP who also ensures
complete information about risks, benefits, and study
procedures etc., based on a patient information sheet
which is prepared according to current ethic committees
standards. Patients can cancel their consent for the trial
at any time without disadvantages.
All data including patient identifiers will be treated
confidentially. The patient declares her agreement to
disclosure of pseudonymised data based on current data
protection regulations.
Registration
This study is registered at clinical trials.gov (Nr. 2011-
002271-42) with the acronym ICUTI.
Discussion
This study aims at investigating whether the use of anti-
biotics for uncomplicated UTI could be reduced by initial
treatment with ibuprofen. The comparative effectiveness
design was chosen to prove the effectiveness of two thera-
peutic strategies instead of the pure drug efficacy. This ap-
proach, fitting in the daily routines of UTI management in
primary care [19], can eventually alter the way in which
treatment of UTI is usually practiced. ICUTI is designed to
create evidence for an alternative treatment option without
antibiotics and to provide information about risks and ben-
efits of both treatment strategies.
While working out the study design, we considered dif-
ferent methodological approaches, one of which would
have been a non-inferiority trial with a placebo-group [20].
This could also have demonstrated the superiority of the
other two treatment strategies over placebo, but we decided
that these methodological benefits did not warrant with-
holding available treatments from patients who suffer from
acute UTI. Therefore we decided against this approach.
Many UTI trials focus on patients with microbiologic-
ally proven UTI. We decided to follow a more pragmatic
approach by including patients presenting with typical
symptoms. The resulting study population represents
“typical” patients with uncomplicated lower UTI who
are otherwise healthy.
Urine cultures will only be provided for trial reasons on
day 0 to assess bacterial count and species, to be able to
discriminate patients with and without bacterial infections
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in the analysis, and to have data on resistance in case a sec-
ondary antibiotic treatment is needed. This is in line with
general practitioners’ routine and general practice guide-
lines – treatment decisions in uncomplicated UTI are
usually made without microbiological specification.
Procedures
To optimize external validity, study-related changes of
usual general practice procedures are minimized. There-
fore, in line with routine GP procedures in primary care,
study visits are restricted to inclusion on day 0. Further
study visits are not mandatory. However, patients are
instructed to return to see their doctor in case of persist-
ent or recurrent symptoms, or if they wish to consult for
other reasons.
Trial drug
For immediate antibiotic therapy, fosfomycin-trometamol
was chosen as first line treatment. The German UTI guide-
line recommends fosfomycin-trometamol as one of the first
line treatment options [2,3], since its resistance rates with
regard to E. coli are low [21] and symptoms are treated ef-
fectively. For UTI, a single dose treatment has been shown
to be efficient, serving as comparator in other studies as
well [22-24].
Considering symptom relief as the most important factor
for UTI patients [25], we chose ibuprofen for the interven-
tion group. Ibuprofen is known to be efficient for pain re-
duction in many conditions. It is safe and efficient for pain
control and shows anti-inflammatory activity.
Outcomes
Studies on dose reduction or delayed treatment always
have to address benefit and risk simultaneously. In this
case, the benefit consists of a reduced number of anti-
biotic prescriptions, implying less resistance develop-
ment and fewer side effects, whereas the potential risk
of higher symptom burden has to be considered care-
fully. Therefore, we chose a combined primary endpoint
with two components such as symptom course within
7 days and antibiotic usage up to day 28. Additionally,
safety criteria will be assessed by several safety endpoints
such as number of AE and SAE up to day 28.
Safety
Treatment courses are very short in both groups. Empiric-
ally, adverse drug effects should occur less frequently with
ibuprofen than with antibiotic therapy. Complicated disease
courses are not expected, since UTI is a non-serious condi-
tion. The risk of pyelonephritis after non-antibiotic treat-
ment of UTI is often mentioned, but little data exists. In
one trial comparing antibiotic versus placebo treatment in
patients with UTI 1 of 38 patients treated with placebo was
suspected to have a pyelonephritis [12,26]. To avoid safety
risks, study patients are instructed to reconsult in case of
persistent/worsening symptoms. Patients with fever have to
be reported immediately. To assess a long-term-follow up,
telephone interviews will be conducted after 6 and
12 months.
Conclusions
This trial may provide evidence for effectiveness for a new,
non-antimicrobial treatment approach in general practice
as indicated in the pilot study (HWI −01). If it could be
shown that this strategy allows for a substantial reduction
of antibiotics while being symptomatically effective and
safe, treatment recommendations should be changed: anti-
inflammatory agents as first choice therapy for uncompli-
cated UTI, and antibiotic treatment only for those who re-
turn with persisting or recurrent symptoms. Thus, the
individual patient and society benefit from a reduced rate
of antibiotic consumption reducing the pressure on resist-
ance development.
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